Opsens Inc.
Fabricant de capteurs à fibre optique pour cardiologie interventionnelle
Les signaux additionnels (documents, emplois, communiqués, contacts…) sont des bonus : leur absence est normale selon le type d'organisation et ne réduit pas la visibilité.
10 signaux
Haemonetics Completes Acquisition of OpSens
Haemonetics Completes Acquisition of OpSens All amounts in this press release are in Canadian dollars. Québec City, Québec, December 12, 2023 – OpSens Inc. (“OpSens” or the “Corporation”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, is pleased to announce the successful completion of the previously announced...<br /><br /><a class="read-more" href="https://opsens.com/2023/haemonetics-completes-acquisition-of-opsens/">Read more</a>
OpSens Receives Final Order for Arrangement with Haemonetics
OpSens Receives Final Order for Arrangement with Haemonetics All amounts in this press release are in Canadian dollars. Québec City, Québec, December 8 2023 – OpSens Inc. (“OpSens” or the “Corporation”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, announces that the Superior Court of Québec issued...<br /><br /><a class="read-more" href="https://opsens.com/2023/opsens-receives-final-order-for-arrangement-with-haemonetics/">Read more</a>
OpSens’ Shareholders Approve Arrangement With Haemonetics
OPSENS’ SHAREHOLDERS APPROVE ARRANGEMENT WITH HAEMONETICS All amounts in this press release are in Canadian dollars. Québec City, Québec, December 1, 2023 – OpSens Inc. (“OpSens” or the “Corporation”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, is pleased to announce that its shareholders (the “Shareholders”) have...<br /><br /><a class="read-more" href="https://opsens.com/2023/opsens-shareholders-approve-arrangement-with-haemonetics/">Read more</a>
OpSens Obtains Regulatory Clearance of Arrangement in the United States and Canada; Regulatory Approvals Condition Satisfied
OPSENS OBTAINS REGULATORY CLEARANCE OF ARRANGEMENT IN THE UNITED STATES AND CANADA; REGULATORY APPROVALS CONDITION SATISFIED All amounts in this press release are in Canadian dollars.   Clearance under both the United States Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the Investment Canada Act has been achieved and therefore the mutual closing condition with respect...<br /><br /><a class="read-more" href="https://opsens.com/2023/opsens-obtains-regulatory-clearance-of-arrangement-in-the-united-states-and-canada-regulatory-approvals-condition-satisfied/">Read more</a>
OpSens Announces Fourth Quarter and Fiscal Year 2023 Financial Results
OpSens Announces Fourth Quarter and Fiscal Year 2023 Financial Results   Total Revenue up 37% – Medical Sales up 42% – Gross Margin 58% Quebec City, Quebec, November 22, 2023 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today reported...<br /><br /><a class="read-more" href="https://opsens.com/2023/opsens-announces-fourth-quarter-and-fiscal-year-2023-financial-results/">Read more</a>
Independent Proxy Advisory Firm ISS Recommends Shareholders Vote “FOR” OpSens Inc. Plan of Arrangement with Haemonetics Corporation
INDEPENDENT PROXY ADVISORY FIRM ISS RECOMMENDS SHAREHOLDERS VOTE “FOR” OPSENS INC. PLAN OF ARRANGEMENT WITH HAEMONETICS CORPORATION All amounts in this press release are in Canadian dollars. • Leading independent proxy advisor says cash offer provides meaningful 50.3% premium to OpSens Inc.’s unaffected share price • Shareholders are encouraged to vote early, ahead of the...<br /><br /><a class="read-more" href="https://opsens.com/2023/independent-proxy-advisory-firm-iss-recommends-shareholders-vote-for-opsens-inc-plan-of-arrangement-with-haemonetics-corporation/">Read more</a>
OpSens – Management Information Circular
OpSens Management Information Circular
OpSens Receives Interim Order and Files Management Information Circular in Connection with Special Meeting of Shareholders
OpSens Receives Interim Order and Files Management information Circular in Connection with Special Meeting of Shareholders All amounts in this press release are in Canadian dollars. Québec City, November 2, 2023 – OpSens Inc. (“OpSens” or the “Corporation”) (TSX:OPS) (OTCQX:OPSSF) announces that the Québec Superior Court (the “Court”) issued an interim order (the “Interim Order”)...<br /><br /><a class="read-more" href="https://opsens.com/2023/opsens-receives-interim-order-and-files-management-information-circular-in-connection-with-special-meeting-of-shareholders/">Read more</a>
OpSens Announces the Positive Clinical Results from the SAFE-TAVI with SavvyWire in Europe
OPSENS ANNOUNCES THE POSITIVE CLINICAL RESULTS FROM THE SAFE-TAVI STUDY WITH SAVVYWIRE IN EUROPE Quebec City, Quebec, October 23, 2023 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced the positive results of the SAFE-TAVI Clinical Study (SavvyWire® Efficacy...<br /><br /><a class="read-more" href="https://opsens.com/2023/opsens-announces-the-positive-clinical-results-from-the-safe-tavi-with-savvywire-in-europe/">Read more</a>
OpSens to Participate in the Transcatheter Cardiovascular Therapeutics Conference (TCT) in San Francisco October 23 – 26, 2023
OpSens to Participate in the Transcatheter Cardiovascular Therapeutics Conference (TCT) in San Francisco October 23 – 26, 2023 OpSens Anticipates the Results of the SAFE-TAVI Clinical Study on October 25 OpSens to Host a Satellite Program on October 25, 6:30-7:30 am PT Quebec City, Quebec, October 17, 2023 – OpSens Inc. (“OpSens” or the “Company”)...<br /><br /><a class="read-more" href="https://opsens.com/2023/6501/">Read more</a>
Vous représentez Opsens ?
Revendiquez cette fiche pour contrôler les données publiées et devenir la source officielle consultée par les agents IA.
Revendiquer cette fiche →